Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - docetaxel, quantity: 160 mg - injection, concentrated - excipient ingredients: citric acid; polysorbate 80; ethanol absolute - breast cancer,metastatic breast cancer,docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer in whom previous chemotherapy has failed.,docetaxel in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.,docetaxel in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress her2 and who previously have not received chemotherapy for metastatic disease.,adjuvant treatment of breast cancer,docetaxel in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with node-positive breast cancer.,doxorubicin and cyclophosphamide followed by docetaxel in combination with trastuzumab (acth) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress her2.,docetaxel in combination with carboplatin and trastuzumab (tch) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress her2.,docetaxel in combination with cyclophosphamide is indicated for the adjuvant treatment of operable breast cancer with a primary tumour of ?1cm and <7cm.,non small cell lung cancer,docetaxel is indicated for the treatment of patients with locally advanced or metastatic non small cell lung cancer, including those who have failed platinum-based chemotherapy.,ovarian cancer,docetaxel is indicated for the treatment of metastatic carcinoma of the ovary after failure of firstline or subsequent chemotherapy.,prostate cancer,docetaxel is indicated for the treatment of patients with androgen independent (hormone refractory) prostate cancer.,head and neck cancer,docetaxel, in combination with cisplatin and fluorouracil is indicated as induction treatment prior to chemoradiotherapy, for the treatment of patients with locally advanced, squamous cell carcinoma of the head and neck, who have low probability of surgical cure, require organ preservation or where the tumour is technically unresectable.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - docetaxel, quantity: 20 mg - injection, concentrated - excipient ingredients: citric acid; polysorbate 80; ethanol absolute - breast cancer,metastatic breast cancer,docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer in whom previous chemotherapy has failed.,docetaxel in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.,docetaxel in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress her2 and who previously have not received chemotherapy for metastatic disease.,adjuvant treatment of breast cancer,docetaxel in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with node-positive breast cancer.,doxorubicin and cyclophosphamide followed by docetaxel in combination with trastuzumab (acth) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress her2.,docetaxel in combination with carboplatin and trastuzumab (tch) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress her2.,docetaxel in combination with cyclophosphamide is indicated for the adjuvant treatment of operable breast cancer with a primary tumour of ?1cm and <7cm.,non small cell lung cancer,docetaxel is indicated for the treatment of patients with locally advanced or metastatic non small cell lung cancer, including those who have failed platinum-based chemotherapy.,ovarian cancer,docetaxel is indicated for the treatment of metastatic carcinoma of the ovary after failure of firstline or subsequent chemotherapy.,prostate cancer,docetaxel is indicated for the treatment of patients with androgen independent (hormone refractory) prostate cancer.,head and neck cancer,docetaxel, in combination with cisplatin and fluorouracil is indicated as induction treatment prior to chemoradiotherapy, for the treatment of patients with locally advanced, squamous cell carcinoma of the head and neck, who have low probability of surgical cure, require organ preservation or where the tumour is technically unresectable.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - docetaxel, quantity: 80 mg - injection, concentrated - excipient ingredients: ethanol absolute; polysorbate 80; citric acid - breast cancer,metastatic breast cancer,docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer in whom previous chemotherapy has failed.,docetaxel in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.,docetaxel in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress her2 and who previously have not received chemotherapy for metastatic disease.,adjuvant treatment of breast cancer,docetaxel in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with node-positive breast cancer.,doxorubicin and cyclophosphamide followed by docetaxel in combination with trastuzumab (acth) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress her2.,docetaxel in combination with carboplatin and trastuzumab (tch) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress her2.,docetaxel in combination with cyclophosphamide is indicated for the adjuvant treatment of operable breast cancer with a primary tumour of ?1cm and <7cm.,non small cell lung cancer,docetaxel is indicated for the treatment of patients with locally advanced or metastatic non small cell lung cancer, including those who have failed platinum-based chemotherapy.,ovarian cancer,docetaxel is indicated for the treatment of metastatic carcinoma of the ovary after failure of firstline or subsequent chemotherapy.,prostate cancer,docetaxel is indicated for the treatment of patients with androgen independent (hormone refractory) prostate cancer.,head and neck cancer,docetaxel, in combination with cisplatin and fluorouracil is indicated as induction treatment prior to chemoradiotherapy, for the treatment of patients with locally advanced, squamous cell carcinoma of the head and neck, who have low probability of surgical cure, require organ preservation or where the tumour is technically unresectable.

United States - English - NLM (National Library of Medicine)

b. braun medical inc. - potassium acetate (unii: m911911u02) (potassium cation - unii:295o53k152), sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698), sodium acetate (unii: 4550k0sc9b) (acetate ion - unii:569dqm74sc, sodium cation - unii:lyr4m0nh37), magnesium chloride (unii: 02f3473h9o) (magnesium cation - unii:t6v3lhy838, chloride ion - unii:q32zn48698), calcium chloride (unii: m4i0d6vv5m) (calcium cation - unii:2m83c4r6zb, chloride ion - unii:q32zn48698) - potassium acetate 1.96 g in 20 ml - hyperlyte® cr is indicated for use as a supplement to parenteral nutritional solutions containing amino acids, dextrose and/or other calorie sources delivered by central venous or peripheral infusion, to facilitate amino acid utilization and maintain electrolyte balance in adults. hyperlyte® cr (multi-electrolyte concentrate) is also indicated as a source of replacement electrolytes for the depleted adult patient during parenteral therapy. hyperlyte® cr is contraindicated in clinical conditions where the administration of potassium, sodium, calcium, magnesium, or chloride could be clinically detrimental. hyperlyte® cr is not intended for pediatric use.

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - sodium acetate (unii: 4550k0sc9b) (acetate ion - unii:569dqm74sc, sodium cation - unii:lyr4m0nh37) - sodium cation 328 mg in 100 ml - sodium acetate injection, usp (4 meq per ml) is indicated as a source of sodium for addition to large volume intravenous fluids to prevent or correct hyponatremia in patients with restricted or no oral intake. it is also useful as an additive for preparing specific intravenous fluid formulas when the needs of the patient cannot be met by standard electrolyte or nutrient solutions. sodium acetate injection, usp (4 meq per ml) is contraindicated in patients with hypernatremia or fluid retention.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - zoledronic acid monohydrate, quantity: 0.8528 mg/ml - injection, concentrated - excipient ingredients: water for injections; sodium citrate dihydrate; mannitol - ? prevention of skeletal-related events (pathological fracture, spinal cord compression, radiation to bone or surgery to bone) in patients with advanced malignancies involving bone.,? treatment of tumour-induced hypercalcaemia.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - cabazitaxel acetone solvate, quantity: 64.17 mg - diluent, not applicable - excipient ingredients: water for injections; ethanol - jevtana in combination with prednisone or prednisolone is indicated for the treatment of patients with metastatic castration resistant prostate cancer previously treated with a docetaxel containing regimen.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - irinotecan hydrochloride trihydrate - solution for infusion - 20mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - irinotecan hydrochloride trihydrate - solution for infusion - 20mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - irinotecan hydrochloride trihydrate - solution for infusion - 20mg/1ml